Short answer
REGENXBIO Inc. (RGNX) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $100 million milestone earned from AbbVie under amended collaboration and license agreement.
REGENXBIO Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $100 million milestone earned from AbbVie under amended collaboration and license agreement
- Triggered by first patient dosing in Phase IIb/III diabetic retinopathy trial
- Sura-vec uses suprachoroidal delivery, advancing ABBV-RGX-314 toward pivotal-stage development
- Cash expected in July 2026, strengthening near-term liquidity without disclosed new debt
Item EX-99.1 · Exhibit EX-99.1
- First patient dosed in Phase IIb/III NAAVIGATE trial for diabetic retinopathy, advancing sura-vec toward pivotal testing
- $100 million AbbVie milestone payment, creating near-term non-dilutive cash inflow
- Phase IIb expected to enroll approximately 135 U.S. participants; primary endpoint is one-year DRSS improvement
- Two-year ALTITUDE data showed durable efficacy and no intraocular inflammation in dose-level 3 patients (n=15)
- AbbVie-partnered wet AMD pivotal-trial topline data expected in Q4 2026, adding a major near-term catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other REGENXBIO Inc. 8-K filings
Get the next RGNX 8-K as it lands
Follow RGNX for push alerts, or ask the research agent what this filing means.